ArticleMedicine2025
CD45 on CD33br HLA-DR+ immune cells promote cholecystitis via glycine-mediated pathways: A Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Over the past 2 decades, the prevalence of cholecystitis has increased significantly, a trend believed to be influenced by improvements in quality of life and changes in lifestyle habits. However, the precise etiology of cholecystitis remains unclear. Although gallstones are commonly associated with this condition, recent studies suggest that immune cells also play a critical role in their development. This study investigated the relationship between cholecystitis and CD45 on CD33br HLA-DR+ immune cells, focusing on the mediating role of glycine levels, using Mendelian randomization (MR). The primary analytical approach employed was inverse variance weighting (IVW) complemented by additional methods, such as MR-Egger, weighted median, simple mode, and weighted mode. Horizontal pleiotropy and heterogeneity were evaluated to ensure the robustness of the MR findings, and a "leave-one-out" analysis was conducted to explore potential mediating effects. IVW analysis revealed that the association between cholecystitis and CD45 on CD33br HLA-DR+ immune cells yielded an odds ratio of 1.039 (95% confidence interval: 1.012-1.067, P = .004). Mediation analysis further indicated that glycine levels mediated this relationship, with a significant mediating effect of 6.87% (P = .0046). Notably, cholecystitis did not exhibit a reverse causal effect of CD45 on CD33br HLA-DR+ levels (P = .545; IVW odds ratio = 1.044, 95% confidence interval: 0.907-1.201). These findings suggested that the association between CD45 on CD33br HLA-DR+ immune cells and cholecystitis is mediated by glycine levels. This study provides novel insights into cholecystitis pathogenesis, highlighting the potential role of metabolic factors in immune-mediated inflammation. These results offer a new perspective on the underlying mechanisms of cholecystitis and suggest potential metabolic intervention targets for its prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.